Exchange: NYSE·Updated 07:30 PM EDT

RVTY News

News
all
press releases
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
Zacks
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
Zacks
More News
Envista Q3 Earnings Ahead: Product Innovation to Drive Growth
NVST's Q3 earnings may have gained from Spark aligner growth, new product launches and improving margins. Can innovation drive another earnings beat?
Zacks
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks
Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Henry Schein to Report Q3 Earnings: Here's What You Should Know
HSIC gears up for Q3 earnings with revenue growth expected across its three segments, fueled by dental products, specialty demand and cloud-based technology.
Zacks
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
CareDx's Q3 earnings are in focus as transplant testing growth, stronger reimbursement and oncology expansion drive revenue prospects despite potential margin pressures.
Zacks
ELV vs. RVTY: Which Stock Is the Better Value Option?
ELV vs. RVTY: Which Stock Is the Better Value Option?
Zacks
Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings
IDXX heads into Q3 earnings with expected revenue and EPS growth, fueled by CAG Diagnostics momentum, higher testing volumes and software gains.
Zacks
Revvity Launches Signals LabGistics to Coordinate Scientific Workflows
RVTY's AI-first Signals LabGistics aims to streamline scientific workflows, enhance R&D-to-manufacturing coordination and expand software growth opportunities.
Zacks

Advertisement|Remove ads.